1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsDrug Discovery for Gastrointestinal Motility Disorders Using hPSC-Derived Enteric Ganglioids is sponsored by California Institute for Regenerative Medicine (CIRM). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Drug discovery for gastrointestinal motility disorders using hPSC-derived enteric ganglioids – CIRM Drug discovery for gastrointestinal motility disorders using hPSC-derived enteric ganglioids Quest – Discovery Stage Research Projects University of California, San Francisco Intestinal Disease , Metabolic Disorders Grant Application Details Drug discovery for gastrointestinal motility disorders using hPSC-derived enteric ganglioids Our goal is to use stem cell models to identify a small molecule drug candidate for GI motility disorders.
The candidate will be used for severe gastrointestinal motility disorders including chronic constipation, achalasia and gastroparesis.
Major Proposed Activities Assessment of candidate compounds on stem cell derived models from diverse genetic backgrounds Evaluation of effectiveness on mouse tissue Understanding the underlying therapeutic effect of the drug candidates Identification of the best performing drug candidate for follow-up assessment in animal models Evaluation of safety and dosing regimen in animal models Testing the effectiveness of drug candidate in animal models Statement of Benefit to California: Gastrointestinal motility disorders are highly common and affect a large patient population in California.
Currently available treatment options are limited and ineffective leading to reduced quality of life and increased burden of care.
According to the current listing, eligibility includes: Academic institutions, research organizations, and biotech companies in California. Confirm the full requirements in the official notice before applying.
The current listing shows $1,954,367. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Drug Discovery for Gastrointestinal Motility Disorders Using hPSC-Derived Enteric Ganglioids is funded by California Institute for Regenerative Medicine (CIRM). Verify program details on the funder's official page before applying.
This opportunity targets applicants in California. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Preclinical Development (PDEV) program is sponsored by California Institute for Regenerative Medicine (CIRM). The PDEV program supports preclinical development of stem cell-based and genetic therapies that offer potential for transformative clinical impact and address current barriers to patient access. This includes research on stem cell-derived retinal pigment epithelium (RPE) cells for treating maculopathies and supporting photoreceptors.
CLIN2 Awards: Funding Opportunity for Clinical Trials is sponsored by California Institute for Regenerative Medicine (CIRM). CIRM's CLIN2 Awards program supports the clinical development of stem cell-based and genetic therapy approaches for treating diseases with unmet medical needs. The program aims to expedite clinical development towards late-stage trials through innovative trial designs and strategies for market access and pre-commercialization.
DARPA pre-released Release 6 of its FY26 SBIR BAA on September 2, 2026. Five of the seven SBIR topics belong to the Biological Technologies Office, and four of those describe one continuous problem: keeping a casualty alive with no surgeon, no imaging, and no evacuation. Here are the award sizes, the Direct-to-Phase-II gates, and the sequencing DARPA is buying.
Read articleThe FY2026 MEP Center State Competition ran in two rounds: eight states worth $139.1 million, then fourteen more worth $232.4 million, both closing August 21, 2026. That's 43 percent of the national network recompeted in twelve months, under a 50 percent non-federal cost share, while the administration's own budget request proposed eliminating the program. Here's what the award tables reveal, why incumbents are genuinely at risk, and how to position for the FY2027 wave.
Read articleOn August 14, 2026, the California Arts Council approved nearly $24.6 million across 1,200 grant awards. Buried in the release is a rare thing: before-and-after data showing exactly how much the ranked-priority bonus moved the pool. Small organizations went from 53% of applicants to 72% of awardees. Geography moved 19 points. First-time status barely moved at all. Here is what that means for the 2027 cycle.
Read article